SCHEMBL5544124

SCHEMBL5544124

COc1cc(OC)c(NC2CCN(c3ccc(O)cc3)CC2)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 5/20 0.46
EHMT2 Q96KQ7 3/20 0.44
TYR P14679 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
POLB P06746 2/20 0.42
MAPT P10636 4/20 0.42
GFER P55789 3/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
LMNA P02545 1/20 0.41
ABCB1 P08183 2/20 0.41
L3MBTL1 Q9Y468 3/20 0.41
ME3 Q16798 1/20 0.41
HSD17B10 Q99714 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544117 0.87 EHMT2 (0.44) GAAEHMT2MEN1KMT2APOLB
SCHEMBL27629458 0.80 HTR1A (0.43) GAATYRMEN1KMT2APOLB
SCHEMBL5544175 0.78 TYR (0.53) GAATYRKMT2AMAPTGFER
SCHEMBL5546024 0.76 ME3 (0.44) GAAEHMT2MEN1KMT2AMAPT
SCHEMBL5537866 0.75 L3MBTL1 (0.53) GAATYRKMT2APOLBMAPT
SCHEMBL5546075 0.71 GAA (0.52) GAATYRMEN1KMT2AMAPT
SCHEMBL5537153 0.71 ME3 (0.52) GAAMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL13090000 0.70 L3MBTL1 (0.62) GAAMEN1KMT2APOLBMAPT
SCHEMBL2092594 0.70 ALDH1A1 (0.38) GAAEHMT2MEN1KMT2AMAPT
SCHEMBL27666071 0.70 EHMT2 (0.48) EHMT2KDM4EALDH1A1LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 GAA 4165/4885EHMT2 2971/4885TYR 4665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.